ResMed’s competitive edge is strong, but its current valuation seems inflated. Read why RMD stock might be ripe for ...

Medical device company ResMed (NYSE:RMD) announced in Q4 CY2024, with sales up 10.3% year on year to $1.28 billion. Its ...

In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...

ResMed (NYSE:RMD) received an updated price target from RBC Capital Markets following the disclosure of its second-quarter ...

The decline in stock value comes as analysts express mixed views on the company's quarterly performance. While ResMed achieved a 10% revenue increase compared to the same quarter last year, some ...

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

Stifel Nicolaus analyst Jonathan Block maintained a Hold rating on Resmed (RMD – Research Report) today and set a price target of $250.00. The ...

Needham analyst Michael Matson has maintained their neutral stance on RMD stock, giving a Hold rating on January 29.Invest with Confidence: ...

Year-over-year revenue grows 10%, operating profit up 52%, non-GAAP operating profit up 19%Operating cash flow of $309 million Note: A webcast of ResMed's conference call will be available at 4:30 p.m ...

ResMed Inc (RMD) reports a 10% revenue increase and significant margin expansion, driven by robust device sales and strategic global expansion.

Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...

ResMed boss Mick Farrell says the new Trump administration could be a tailwind for the company, likely locking in a ...